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Summary 
Background: Breast cancer (BC) survivors are at increased risk of second cancers. Obesity is 
commonly recognized as a risk factor of breast cancer in postmenopausal period and a 
prognosis factor in breast cancer regardless of menopausal status. Our  aim was to study 
whether overweight breast cancer survivors were at increased risk of Contralateral Breast 
Cancer (CBC). 
Methods: Our population was a large cohort of women followed since a first BC without 
distant spread and/or synchronous CBC. Body Mass Index (BMI) was assessed at diagnosis 
time. Binary codings of BMI were used to oppose overweight and obese patients to the others. 
Survival analyses were used including Cox models. Assumed hypothesis of proportional 
hazards was explored using graphical methods, Schoenfeld residuals and time-dependant 
covariates. In case of non proportional hazards, survival models were computed over time 
periods. 
Results: Over 15,000 patients were included in our study. Incidence of CBC was 8.8 [8.3-
9.3]/1000 person-years and increased during follow-up. A significant time-dependent 
association between overweight and CBC was observed. After ten years of follow-up, we 
found a significant increased hazard of CBC among patients with a BMI above 25kg/m²: the 
adjusted hazard ratio was 1.50[1.21-1.86], p=0.001.  
Conclusions: After ten years of follow-up, our study found a poorer prognosis among 
overweight breast cancer survivors regarding CBC events. While benefits from diet habits and 
weight control may be expected during the long term follow-up, they have yet to be 
established using randomized clinical trials.   
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A. Introduction 
Numerous studies and literature reviews support the assumption of a poorer prognosis for 
overweight and obese women at the time of breast cancer diagnosis[1, 2]. Therefore, diet 
improvement and physical exercise are recommended among breast cancer patients[3]. 
Furthermore, an observational study found a reduction of mortality among women having 
significant vegetable-fruit intake and physical activity[4]. However, recent clinical trials, 
testing whether intervention regarding diet habits could improve breast cancer outcomes, had 
mixed and conflicting results[5]. Nevertheless, in these trials, the follow-up duration was 
limited to less than ten years. Modification of diet and exercise habits may have an effect on 
prognosis on a longer term. In addition, prognosis improvement in relation to lifestyle habits 
may depend on the outcome of interest.  
In breast cancer prognosis studies, the main investigated endpoints in published literature are 
overall survival and disease free survival that includes distant, regional and local relapses. 
Contralateral breast cancer (CBC) occurrences have seldom been explored as a specific 
outcome among women having previously had a first breast cancer. Breast cancer patients are 
recognized at an increased risk of second primary cancers including CBC, when compared to 
the general population[6, 7]. The cumulative incidence of CBC occurrences has been 
estimated to be of 4% at 5 years of follow-up[8] and more than 10% after 10 years of follow-
up [7, 9]. A cumulative hazard of 20% has been reported after a follow-up of 20 years[10]. 
Obesity has been previously associated with an increased risk of CBC[11]; however, evidence 
regarding this association remains sparse. After a first occurrence of breast cancer (BC), a 
CBC event is usually considered as a second primary cancer[8].  
Previously, we analyzed and confirmed the prognosis value of obesity and overweight in 
women breast cancer[12]. Different end points were explored including CBC occurrences. 
The association between body mass index (BMI) and CBC occurrences was not statistically 
significant; however, descriptive analysis suggested an increase of CBC events among 
patients with high values of BMI on the long term follow-up.  
Whilst breast cancer patients are at increased risk of CBC, obesity represents a reliable breast 
cancer risk factor in the post-menopausal period[13]. We hypothesized that being overweight 
at the time of a first breast cancer diagnosis, may represent a risk factor for CBC during the 
follow-up. We also sought for a long term association assuming a time-dependent 
relationship. During the follow-up, aging leads to an increase of women with a post-
menopausal status. In addition, aging and breast cancer treatment are also known to be 
associated with weight gain[14-16]. 
In presence of an increase of breast cancer survivors[17], of an increased CBC risk among 
breast cancer patients[18] and of a worldwide obesity epidemic[19], we investigated a 
potential association between BMI and CBC events. Evolution of CBC hazard during the 
follow-up was assessed. Common explanatory factors of CBC risk were also explored. 
B. Material and Methods 
a. Material 
The Curie Institute is a French Institute of Cancer Research and Treatment. Characteristics of 
recruited patients for treatment were available in a large and regularly updated data-base. 
Thus, we constituted a large cohort of women treated and followed since a first unilateral 
invasive non metastatic breast cancer. Period of recruitment extended from January 1981 to 
December 1999. Patients with synchronous CBC, defined by the occurrence of a CBC within 
the first six months of follow-up, were excluded. The aim of our study was to investigate the 
risk of metachronous CBC.  
Weight and height were assessed at diagnosis time. Hence, patients’ BMI was computed and 
used to define overweight and obesity, according to World health organization 
recommendations[20]. Two thresholds were used to define binary codings of BMI. The first 
coding grouped overweight and obese women using 25 kg/m² as a cut-off. The second coding 
individualized obese patients using 30 kg/m² as a cut-off. Patients with unavailable data 
regarding height or weight were excluded. They represented less than 15% of the initial 
eligible population.   
b. Methods 
i. Descriptive and univariate analysis 
An estimation of CBC incidence, using the actuarial survival method, was performed to assess 
the evolution of CBC hazard during follow-up[21]. A Poisson regression was used to test a 
significant increase of incidence during follow-up. Cumulative hazard rates of CBC, using the 
Nelson-Aalen estimator, were also computed[22]. 
Documented risk factors for CBC[6, 18] such as lobular histology of the first breast cancer, 
age, family history of BC, method of treatment (chemotherapy, hormonotherapy) were 
investigated in our population. Association between BMI and the hazard of CBC was 
explored, using independently the two binary codings of BMI cited above. We computed 
Kaplan Meier survival curves, log-rank tests and estimation of Hazard Ratios (HR) using a 
semi-parametric survival model (Cox model) assuming proportional hazards[22]. 
ii. Testing the non-proportional hazards assumption 
Different strategies are proposed to verify the proportional hazard hypothesis and to handle a 
violation of the proportional hazard assumption when a Cox model is used[22].  
A crude method is the graphical representation of survival curves to assess the assumption of 
proportional hazards. It can be used with variables with a limited number of categories. A 
complementary reliable tool to consider non proportional hazards consists in testing the 
relevance of a time-dependent coefficient in the Cox model. In the usual semi-parametric 
proportional survival model, the hazard at time t is modeled as: XtXt exp)(),( 0 , 
where )(0 t  is an unspecified function of time (t), a vector of coefficients assumed constant 
in time and X the matrix of covariates. Whilst a time-dependent covariate is considered, the 
model becomes: XttXt )(exp)(),( 0 , where  vary according to time (t) or a function 
of time. We employed a logarithmic transformation of time (as a function of time) when 
testing proportional hazards with a time-dependent covariate. Finally, Therneau and 
Grumbsch suggest the use of a test for non-proportionality and to assess the variation over 
time of a Cox model coefficient using scaled Schoenfeld residuals[22]. 
Consequently, we investigated a possible variation during follow-up of the association 
between BMI and CBC events using the methods cited above.  
iii. Handling an association between BMI and CBC risk in presence of 
non-proportional hazards  
In case of non-proportional hazards, we partitioned the time axis. To this end, we defined time 
periods using the shape of time-dependent hazards. In each time period, common proportional 
HR, opposing heavier patients to others, were computed. Proportional hazards assumption 
was thereafter verified using Schoenfeld residuals’ test.  
Multivariate adjusted analyses were performed using as covariates classical CBC risk factors. 
We also used patients and/or tumor characteristics significantly associated to CBC events in 
our population. 
Since CBC are considered as second primary breast cancers, CBC events were analyzed 
independently from other breast cancer prognosis events.  
R-software, including the “survival” package, was used for the data analysis. 
C. Results 
Characteristics of our population (N=15,166) at the diagnosis time of the first breast cancer 
are summarized in Table 1. The mean age was 54 years. Proportions of menopausal women 
without hormonal replacement therapy and non-menopausal patients were similar; 
menopausal women with hormonal replacement therapy represented 8% of our population. 
Patients with a familial history of breast cancer represented 20% of our population. Obese 
patients, represented 8% and overweight patients represented 22% of our population.  
Most breast cancers were discovered after a clinical palpation (in almost 70% of cases). 
Ductal breast cancers were the most frequent, in 75% of cases. Half of the tumors had 
hormone receptors. Stage I and II breast cancers represented 85% of the cases.  
Almost two third of patients had conservative surgery. Adjuvant treatments (chemotherapy 
and/or hormonotherapy) were used in 49% of patients. 
The median of follow-up was 10 years and the maximal follow-up was 24 years. Observed 
number of CBC events during follow-up was 1,370. Annual incidence of CBC was 8.8 [8.3-
9.3]/1000 person-years. A significant increase of annual incidence was observed during the 
follow-up (Figure 1). Cumulative hazards of CBC at 5, 10, 15, 20 and 24 years of follow-up 
were respectively 3.7% [3.4-4.0], 8.3% [7.7-8.8], 13.6% [12.8-14.5], 20% [18.5-21.4] and 
25.5% [22.8-28.2]. 
Among patient characteristics (Table 1), younger age and family history of breast cancer were 
highly and significantly associated with an increased risk of CBC. Menopausal status without 
hormone replacement was associated with a decrease of CBC risk. Patients recruited more 
recently were less at risk of CBC; these patients have had a shorter follow-up.  
The number of axillary involved nodes was the only initial tumor characteristic associated 
with CBC hazard. Patients with involved axillary nodes, after axillary dissection, had a 
decreased risk of CBC. 
Considering treatment strategies, while the use of adjuvant chemotherapy and/or 
hormonotherapy was associated with a reduction of CBC occurrences, neoadjuvant 
chemotherapy and higher doses of radiotherapy were associated with an increase of CBC 
events. Patients who did not benefit from a surgical treatment experienced also more CBC 
events during the follow-up. However, only the use of adjuvant treatments presented a 
statistically significant association with CBC hazard. The more important CBC risk reduction 
was linked to the use of an adjuvant hormonotherapy.  
Whilst the association between BMI and CBC hazard was inconclusive over the total period 
of follow-up (Table 2), a possible violation of non-proportional hazards was considered. Over 
the total period of follow-up, the association between CBC risk and binary coding of BMI 
using the 25kg/m² cut-off was close to the signification threshold of 5% in unadjusted analysis 
and reached signification in adjusted analysis. This result suggested that overweight and obese 
patients were at increased risk of CBC. Nonetheless, on one hand a modest association was 
found and on the other hand tests for non-proportionality were highly significant suggesting a 
violation of the proportional hazards assumption. The binary coding of BMI using the 
30kg/m² cut-off was not significantly associated to CBC hazard (over the total period of 
follow-up) and tests for non-proportional hazards also supported a variation of hazards over 
time. 
We first sought for graphical signs of non-proportionality. In Figure 2, Kaplan-Meier curves 
highly suggested non proportional hazards regarding the association between BMI and CBC. 
Survival curves steadily drifted apart after 10 years of follow-up; before the tenth year of 
follow-up, the curves were joined. In addition, the test of non-proportional hazards, using 
Schoenfeld residuals, was highly significant independently of the BMI coding. Graphical 
results suggested the presence of a significant association between BMI and CBC hazard after 
10 years of follow-up. Time-dependent covariates supported a progressive increase of CBC 
risk among heavier patients during the follow-up, independently of the BMI coding. Figure 3 
illustrate results using BMI 25kg/m² cut-off. These results were similar to those using the 
30kg/m² cut-off (Results not shown). The consistency of the used time-dependent covariates 
was supported by insignificant tests regarding non-proportionality using Schoenfeld residuals. 
The analysis regarding the nature of non-proportionality (shape of non-proportional hazards in 
Figure 3) led us to compute proportional survival models over two periods of time: before and 
after 10 years of follow-up.  
Whilst hazards proportionality was assessed and verified, significant and consistent 
associations between binary codings of BMI and CBC events were found after ten years of 
follow-up (Table 4). An increased risk of CBC among overweight and obese patients was 
highlighted in these analyses. Among overweight and obese patients, adjusted HR reached a 
value of approximately 1.50.  
While at initial follow-up, 60% of patients were over 50 years old, at 10 years of follow-up 
90% of our population was assumed to be over 50 years old. The proportion of menopausal 
women is assumed to have increased importantly. An interaction analysis regarding CBC 
hazard between BMI and menopausal status at the diagnosis time was thus conducted (Table 
3). The association between BMI and CBC hazard was more important among menopausal 
sub-populations, especially among women with a previous hormonal replacement therapy. 
However, on one hand, none of the associations was statistically significant (in explored sub-
populations defined according to menopausal status) and on the other hand the interaction 
term in a global modeling strategy was insignificant. In addition, the test for non-
proportionality was found to be consistent in some cases (Table 3). Consequently, interaction 
analysis between BMI and menopausal status was inconclusive.  
D. Discussion 
Our survey highlighted a relevant increased risk of CBC during the long term follow-up 
among obese and overweight patients. We formulated and corroborated this association 
considering common epidemiologic evidences represented by: an increase of CBC risk during 
follow-up of breast cancer patients, an increase of breast cancer risk among obese women in 
post-menopausal period and weight gain in women when aging, especially in menopausal 
period and after breast cancer treatment[15, 23]. Our results were achieved based on one of 
the largest cohort of women with breast cancer, with a high number of CBC events and an 
important duration of follow-up. 
In spite of the observational setting of our study, our results indicate that overweight and 
obese patients at the diagnosis time of a first breast cancer have a significant increased risk of 
50% of CBC after ten years of follow-up. After a ten-year period of follow-up, almost all 
patients are assumed to be menopausal and patients initially overweight may have maintained 
or increased their weight. 
Some authors formerly documented a significant association between BMI and the hazard of 
CBC. Dignam et al.[11] asserted that obesity may compromise the long term welfare of breast 
cancer survivors. An increase of approximately 60% of CBC risk was observed among obese 
patients when compared to normal BMI and underweight patients. However, the association 
found in our study is time-dependent. Nonetheless, in some breast cancer studies, several 
prognosis factors have been identified with a time-dependent effect that decreases during the 
follow-up[24-26]. On the contrary, we found that CBC hazard is increased during the long 
term follow-up among overweight and obese patients. Our results can suggest that the benefit 
of diet habits improvement, physical exercise and weight control may be effective among 
long term survivors. However, long term improvement of breast cancer prognosis in relation 
to lifestyle modifications has yet to be demonstrated by clinical trials.   
The epidemiological results, found in our study, are in accordance with previously published 
data[6, 8, 18, 27]. Annual incidence of CBC increases during the follow-up of breast cancer 
survivors. Common CBC risk factors were confirmed in our population, apart from tumor 
lobular histology and hormone receptors[18, 27-31]. When considering BMI as an 
independent risk factor for CBC, CBC events are expected to increase along with improved 
breast cancer survival[29] and the given worldwide epidemic of overweight and obesity[19].  
Hazard of CBC is increased among overweight and obese patients in a similar degree during 
the long term follow-up. This result is in accordance with a previous paper that validated 
25kg/m² as an optimal BMI cut-off to distinguish women with increased hazard of metastasis 
recurrence and mortality in breast cancer[32]. However, breast cancer survivors may have had 
a weight increase during follow-up (while aging and becoming menopausal): overweight 
patients at diagnosis time of the first breast cancer may have become obese at 10 years of 
follow-up.   
Some results in our study support the hypothesis of a hormonal mechanisms to explain the 
association between BMI and CBC hazard[1]. In the interaction analysis (Table 3), most 
important associations between CBC and BMI were observed among menopausal patients 
who had a previous hormonal replacement therapy[33]. The association between BMI and 
CBC hazard was significant over the long term follow-up; this may be linked to an increase of 
menopausal women and possibly obese patients over time. Finally, there was a significant 
protective effect of adjuvant hormonal therapy.  
CBC events were considered in our study as second primary cancers, independently from 
other outcomes following initial breast cancers. The absence of association between common 
breast cancer prognosis factors and CBC hazard supports this assumption. Nevertheless, 
different strategies considering competing risks or multistate modeling approaches have been 
previously compared for the assessment of CBC hazard. Results did not indicate a better 
relevance of the above modeling strategies[8].  
Despite our large scale population and an important number of CBC events, other multicentre 
studies are required to confirm our results. Nonetheless, proportional hazards assumption is 
encouraged to be systematically tested when assessing the association between BMI and 
CBC. The accordance between the different methods used in our study (to test the 
proportional hazards assumption) indicates a reliable appraisal of the nature of the link 
between overweight and CBC hazard during follow-up. 
Benefits from improved diet habits and lifestyle may possibly reduce CBC occurrences during 
the long term follow-up. Albeit, CBC are usually diagnosed as in situ cancers and are often 
less extended tumors than the first breast cancers[34].  
Our results support the need of assessments during the long term follow-up of diet and 
lifestyle interventions. Randomized controlled trials are required to establish the usefulness of 
dietary improvements, weight loss and increase in physical activity in breast cancer 
prognosis[35].  
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Variable Subpopulations N & (%) Unadjusted HR for CBC events  
Variable p-value in the Survival 
model 
Age in years 
[18-35[ 536(3.5) 1.68[1.33-2.12] 
<0.0001 
[35-50[ 4996(32.9) 1.05[0.93-1.18] 
[50-65[ 6421(42.3) 1.00(Reference) 
[65-80[ 2962(19.5) 0.83[0.70-0.98] 
≥80 251(1.7) 0.44[0.18-1.06] 
Hormonal 
status 
Pre-menopausal 6830(45) 1.00(Reference) 
0.02 
Post-menopausal 7142(47.1) 0.86[0.77-0.96] 
Hormone replacement 1194(7.9) 0.83[0.66-1.05] 
Family history 
of breast 
cancer 
No 11970(78.9) 1.00(Reference) <0.0001 
yes 2981(19.7) 1.46[1.30-1.65] 
Unknown 215(1.4) 1.02[0.63-1.65] 
Obesity 
BMI<30kg/m² 13970(92.1) 1.00(Reference) 0.42 
BMI≥30kg/m² 1196(7.9) 1.09[0.89-1.34] 
Overweight 
and obesity 
BMI<25kg/m² 10582(69.8) 1.00(Reference) 
0.06 
BMI≥25kg/m² 4584(30.2) 1.12[1.00-1.26] 
Nature of first 
symptom 
Mammography 3061(20.2) 1.00(Reference) 
0.47 
Tumor 10358(68.3) 0.96[0.84-1.10] 
Other/multiple signs 1747(11.5) 1.05[0.87-1.28] 
Period of 
diagnosis and 
treatment 
[1981-1985] 3187(21) 1.00(Reference) 
<0.01 
]1985-1990] 3950(26.1) 1.17[1.02-1.35] 
]1990-1995] 4457(29.4) 1.11[0.95-1.29] 
]1995-1999] 3572(23.6) 0.90[0.74-1.08] 
 
Table 1: Patients’ features at diagnosis time, (Unknown: Non Available data, HR: Hazard 
Ratio) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Subpopulations N & (%) Unadjusted HR for CBC events  
Variable p-value in the Survival 
model 
Histology of 
the initial 
breast cancer 
Ductal  11280(74.4) 1.00(Reference) 
0.69 
Lobular 1278(8.4) 0.94[0.77-1.15] 
Other 1091(7.2) 1.10[0.91-1.34] 
Unknown 1517(10) 1.03[0.86-1.23] 
Tumor size 
<=1cm] 1835(12.1) 1.00(Reference) 
0.65 
]1-2cm] 3560(23.5) 0.99[0.83-1.18] 
]2-5cm] 6608(43.6) 0.97[0.82-1.14] 
>5cm 2008(13.2) 1.11[0.90-1.37] 
Unknown 1155(7.6) 1.02[0.80-1.31] 
Tumor local 
involvement  
T0 1420(9.4) 1.00(Reference) 
0.58 T1 4834(31.9) 1.02[0.84-1.25] 
T2 6244(41.2) 0.98[0.80-1.19] 
T3 1624(10.7) 1.09[0.86-1.40] 
T4 818(5.4) 1.14[0.83-1.56] 
Unknown 226(1.5) 1.30[0.86-1.97] 
Clinical nodes 
invasion  
N0 10415(68.7) 1.00(Reference) 
0.32 
N1 4520(29.8) 1.09[0.97-1.22] 
N2-N3 161(1.1) 0.77[0.37-1.63] 
NX 70(0.5) 1.41[0.73-2.72] 
Involved 
nodes after 
axillary 
dissection 
0 6362(42) 1.00(Reference) 
0.03 
1 to 3 2490(16.4) 0.81[0.68-0.96] 
>3 1311(8.6) 0.91[0.72-1.15] 
no axillary dissection 3586(23.6) 1.07[0.94-1.21] 
Unknown 1417(9.3) 1.03[0.85-1.25] 
Multifocal 
tumor 
Unifocal tumor 12927(85.2) 1.00(Reference) 
0.92 Multifocal tumor 1311(8.6) 0.96[0.79-1.17] 
Unknown 928(6.1) 1.00[0.82-1.23] 
Estrogen 
Receptors 
Negative 2580(17) 1.00(Reference) 
0.26 Positive 7596(50.1) 0.89[0.76-1.03] 
Unknown 4990(32.9) 0.89[0.76-1.04] 
Progesterone 
Receptors 
Negative 3616(23.8) 1.00(Reference) 
0.34 Positive 7491(49.4) 0.90[0.79-1.03] 
Unknown 4059(26.8) 0.93[0.80-1.08] 
Scarth Bloom 
Richardson 
(SBR) Grade 
Non gradable 1320(8.7) 0.94[0.76-1.16] 
0.53 
I 3355(22.1) 1.00(Reference) 
IIA 3460(22.8) 0.94[0.81-1.10] 
IIB 2931(19.3) 0.94[0.80-1.11] 
III 2555(16.9) 1.10[0.93-1.30] 
Unknown 1545(10.2) 1.01[0.83-1.23] 
Table 1 (continued): Tumor characteristics at diagnosis time, (Unknown: Non Available data, 
HR: Hazard Ratio) 
 
 
Variable Subpopulations N & (%) 
Unadjusted HR for CBC 
events  
Variable p-value in the 
Survival model 
First 
Treatment 
Radiotherapy 2812(18.5) 1.05[0.91-1.21] 
0.08 
Lumpectomy 7984(52.6) 1.00(Reference) 
Mastectomy 2086(13.8) 0.90[0.75-1.08] 
Chemotherapy 2284(15.1) 1.18[1.01-1.37] 
Adjuvant 
therapy 
None 7886(52) 1.00(Reference) 
<0.01 Chemo & Hormonotherapy 4647(30.6) 0.92[0.81-1.04] 
Hormonotherapy alone 2633(17.4) 0.75[0.63-0.88] 
Radiotherapy 
delivered 
dose 
No Radiotherapy 1306(8.6) 1.00(Reference) 
0.16 
<=50Grays 719(4.7) 0.95[0.67-1.35] 
]50-75Grays] 9644(63.6) 1.03[0.83-1.29] 
>75Grays 1315(8.7) 1.28[0.98-1.68] 
Unknown 2182(14.4) 1.05[0.81-1.36] 
Final Surgical 
treatment 
Non conservative 4411(29.1) 1.00(Reference) 
0.14 Conservative 8680(57.2) 0.99[0.87-1.13] 
No surgical treatment 2075(13.7) 1.15[0.97-1.37] 
Table 1 (continued): Delivered treatments for the first breast cancer, (Unknown: Non 
Available data, HR: Hazard Ratio) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI binary 
codings & 
period of follow-
up N events 
Incidence/1000 
person-years HR unadjusted 
Tests 
signification 
(unadjusted) HR adjusted 
Tests 
signification 
(adjusted) 
Obesity cut-off       
Period : 0 to 24 years of follow-up 
BMI < 30kg/m² 13970 1271 8.77[8.29-9.26] 1.00(Reference)  
+ 
1.00(Reference) 
+ BMI ≥ 30kg/m² 1196 99 9.20[7.39-11.02] 1.09[0.89-1.34] 1.19[0.97-1.47] 
Period : 0 to 10 years of follow-up 
BMI < 30kg/m² 13970 879 8.03[7.50-8.56] 1.00(Reference) 
 
1.00(Reference) 
 BMI ≥ 30kg/m² 1196 69 7.78[5.94-9.61] 0.98[0.77-1.25] 1.07[0.84-1.38] 
Period : 10 to 24 years of follow-up 
BMI < 30kg/m² 6818 392 11.09[09.99-12.19] 1.00(Reference) 
* 
1.00(Reference)  
* BMI ≥ 30kg/m² 450 30 15.93[10.23-21.63] 1.46[1.01-2.12] 1.60[1.10-2.34] 
Overweight cut-off       
Period : 0 to 24 years of follow-up 
BMI < 25kg/m² 10582 963 8.59[8.04-09.13] 1.00(Reference)  
++ 
1.00(Reference) 
** 
+ BMI ≥ 25kg/m² 4584 407 9.37[8.46-10.28] 1.12[1.00-1.26] 1.21[1.07-1.36] 
Period : 0 to 10 years of follow-up 
BMI < 25kg/m² 10582 670 7.99[7.39-8.6] 1.00(Reference)  
 
1.00(Reference)  
 BMI ≥ 25kg/m² 4584 278 8.05[7.1-9] 1.02[0.88-1.17] 1.11[0.96-1.28] 
Period : 10 to 24 years of follow-up 
BMI < 25kg/m² 5339 293 10.35[9.17-11.54] 1.00(Reference)  
** 
1.00(Reference) 
** BMI ≥ 25kg/m² 1929 129 14.46[11.97-16.96] 1.42[1.15-1.74] 1.50[1.21-1.86] 
Table 2: Survival proportional models computed by time periods (partition of follow-up 
before and after 10 years). Associations between binary codings of BMI and CBC events were 
unadjusted and adjusted using initial delivered treatments, tumor histology and hormonal 
receptors status, number of axillary invaded nodes, patients’ age, family history of breast 
cancer, menopausal status and period of recruitment.  
Statistical tests were computed at non adjusted and adjusted steps: 
p-values regarding the tests of used covariates in survival models are coded as follow:  
* p<0.05, ** p<0.01, *** p<0.001. 
p-values regarding the non-proportionality tests (using Schoenfeld residuals) are coded as 
follow: + p<0.05, ++ p<0.01, +++ p<0.001.  
 
BMI codings Premenopausal patients 
Menopausal patients 
without hormonal replacement 
Menopausal patients 
with hormonal replacement 
BMI<30kg/m² 1.00(Reference) 1.00(Reference) 1.00(Reference) 
BMI≥30kg/m² 0.90[0.62-1.31] 1.24[0.95-1.61]  1.47[0.64-3.4] 
BMI≥25kg/m² 1.00(Reference) 1.00(Reference) 1.00(Reference) 
BMI≥25kg/m² 1.15[0.96-1.37] + 1.17[0.99-1.38] + 1.27[0.78-2.06] 
Table 3: Interaction analysis between BMI and menopausal status at the diagnosis time 
regarding CBC events. Hazard ratios with 95% CI, p-values of used BMI codings and test 
results of non-proportionality (using Schoenfeld residuals) are reported as in Table 2. 
 
 
Figure 1: Significant increase of contralateral breast cancers hazard during follow up 
 
 
 
 
Figure 2 : Kaplan Meier survival curves indicating non-proportional hazards 
 
 
 
 
 
 
 
Figure 3: Assessment of the nature of non-proportional hazards when patients’ with a 
BMI≥25kg/m² are opposed to the others, using Schoenfeld residuals (on the left) and a time 
dependant covariate (on the right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimation of the time dependent coefficient of obese 
and overweight patients compared to others using 
Schoenfeld residuals from the survival model  
